Core Viewpoint - Yonghe Zhikong announced the public transfer of 51% equity and all debts of its subsidiary, Pule New Energy Technology (Taixing) Co., Ltd, with a listing price of RMB 30.49 million [2] Group 1: Company Actions - The company held meetings on October 10 and October 29, 2025, to approve the transfer of equity and debts of Taixing Pule [2] - The public listing for the transfer occurred from November 4 to November 17, 2025, at a price of RMB 30.49 million [2] - The company received feedback from the Southwest United Property Rights Exchange indicating no interested buyers had registered by the deadline [2] Group 2: Future Considerations - The company will fulfill its information disclosure obligations if it decides to relist the equity in the future [2] - Investors are advised to pay attention to subsequent announcements regarding this matter [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 永和流体智控股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日、2025 年 10 月 29 日召开第五届董事会第二十二次临时会议、第五届监事会第十七次临时会议 及 2025 年第二次临时股东大会，审议通过了《关于拟公开挂牌转让普乐新能源科技 （泰兴）有限公司 51%股权及债权的议案》，同意公司在产权交易所公开挂牌转让 控股子公司普乐新能源科技（泰兴）有限公司（以下简称"泰兴普乐"）51%股权及公 司对泰兴普乐的全部债权，并同意授权公司董事长或董事长授权的代理人负责具体实 施 该 事 项 。 具 体 内 容 详 见 公 司 于 2025 年 10 月 14 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）、《证券时报》和《证券日报》刊登的《关于拟公开挂 牌转让普乐新能源科技（泰兴）有限公司 51%股权及债权的公告》（公告编号： 2025-041）。 2025 年 11 月 4 日至 2025 年 11 月 17 日，公司在西南联合产权交易所首次公开挂 ...

Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

Core Points - Yonghe Intelligent Control Co., Ltd. announced the public transfer of 100% equity in Kunming Medical Oncology Hospital to optimize its industrial structure and improve development quality [1][2] - The initial listing price for the equity transfer is set at no less than 35.93 million yuan, based on the assessed value of the hospital's total equity [1] - In the first half of 2025, Kunming Medical reported a revenue of 11.58 million yuan and a net loss of 6.59 million yuan [1] Financial Summary - As of July 31, 2025, Kunming Medical's audited net assets were 32.45 million yuan, with the assessed total equity value at 35.93 million yuan [1] - The company has previously transferred stakes in other subsidiaries, including 95% of Dazhou Medical Oncology Hospital, 70% of Liangshan High-tech Oncology Hospital, and 73% of Xi'an Medical Oncology Hospital [1]

Core Viewpoint - The BC Battery Index experienced a strong intraday surge, with significant activity among its major constituent stocks, indicating positive market sentiment in the battery sector [1]. Group 1: Stock Performance - Saiwu Technology reached its daily limit up, showcasing robust investor interest [1]. - Zhonglai Co., Ltd. increased by 2.57%, reflecting a positive trend in its stock performance [1]. - Yonghe Intelligent Control rose by 2.35%, indicating strong market confidence [1]. - Haimeixing saw a gain of 1.61%, contributing to the overall positive movement in the index [1]. - Dike Co., Ltd. experienced a 1.41% increase, further highlighting the active trading environment [1].

Core Viewpoint - Yonghe Intelligent Control has initiated a series of asset sales following the abrupt termination of its control change plan, raising significant market attention [1][4]. Group 1: Asset Sale Details - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a minimum listing price of 35.93 million CNY [1]. - This marks the fourth time Yonghe Intelligent Control has publicly listed its oncology hospital assets for sale in the past 12 months, including the transfer of stakes in various other hospitals [2]. - The assessed net assets of Kunming Medical as of July 31, 2025, are 32.45 million CNY, with an appraisal value of 35.93 million CNY, reflecting an increase of 3.47 million CNY and a growth rate of 10.70% [1][2]. Group 2: Financial Performance - For the first seven months of 2025, Kunming Medical reported revenue of 11.58 million CNY and a net loss of 6.59 million CNY, continuing a trend of losses from 2024 [2][3]. - Yonghe Intelligent Control's revenue for the first three quarters of 2025 was 582 million CNY, a year-on-year decline of 7.25%, with a net loss attributable to shareholders of 60.46 million CNY [5]. Group 3: Control Change Attempt - The control change plan involving the transfer of 8% of the company's shares for 320 million CNY was terminated due to the buyer's failure to pay the initial installment [3]. - This was the third failed attempt by the current controlling shareholder to change ownership since taking control in 2019 [3].

Core Viewpoint - The company intends to publicly transfer 100% equity of its wholly-owned subsidiary, Kunming Medical Oncology Hospital Co., Ltd., with a minimum listing price of 35.9277 million yuan, aiming to optimize its industrial structure and enhance the quality of the listed company's development [1] Group 1 - The company is planning to transfer its entire stake in Kunming Medical Oncology Hospital [1] - The initial listing price for the equity transfer is set at no less than 35.9277 million yuan [1] - Following the completion of the transaction, the company will no longer hold any equity in Kunming Medical [1]

Core Viewpoint - The company intends to publicly transfer 100% equity of its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a minimum listing price of 35.93 million yuan, aiming to optimize its industrial structure and enhance the quality of the listed company's development [1]. Group 1 - The company is planning to publicly list the transfer of its subsidiary, Kunming Medical Oncology Hospital [1]. - The minimum listing price for the equity transfer is set at no less than 35.93 million yuan [1]. - Upon completion of the transaction, the company will no longer hold any equity in Kunming Medical [1].

Core Viewpoint - The company intends to publicly transfer 100% equity of its wholly-owned subsidiary, Kunming Medical Oncology Hospital Co., Ltd., with a minimum initial listing price of 35.9277 million yuan [1] Group 1 - Upon completion of this transaction, the company will no longer hold any equity in Kunming Medical, and Kunming Medical will be excluded from the company's consolidated financial statements [1]

Group 1 - The company Yonghe Zhikong plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital to optimize its industrial structure and improve development quality [1] - As of the evaluation benchmark date of July 31, 2025, the audited net assets of Kunming Medical are valued at 32.45 million yuan, with the assessed total equity value at 35.93 million yuan [1] - The initial public transfer price for the 100% equity of Kunming Medical is set at no less than 35.93 million yuan based on the evaluation results [1] Group 2 - For the first half of 2025, Yonghe Zhikong's revenue composition is as follows: industrial sector accounts for 89.41%, medical services and others account for 10.57%, and photovoltaic cell segment accounts for 0.02% [1] - The company's market capitalization is reported to be 2.8 billion yuan [2]